Tags : RAP-MD


Allergan Reports Results of Rapastinel in Four P-III RAP-MD Studies

Shots: The P-III RAP-MD (01,02,03,04) studies involve assessing of Rapastinel (450mg, 225mg) vs PBO as an adjunctive treatment of MDD The P-III RAP-MD-04 study demonstrated unmet 1EPs & 2EPs. RAP-MD (01,02,03) studies resulted that Rapastinel was well tolerated with no psychotomimetic side effects Rapastinel (IV, qw) is a novel anti-depressant, enhanced NMDAR activity by acting […]Read More